US20020198238A1 - Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl - Google Patents

Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl Download PDF

Info

Publication number
US20020198238A1
US20020198238A1 US10/180,399 US18039902A US2002198238A1 US 20020198238 A1 US20020198238 A1 US 20020198238A1 US 18039902 A US18039902 A US 18039902A US 2002198238 A1 US2002198238 A1 US 2002198238A1
Authority
US
United States
Prior art keywords
compound
accordance
polymorph
iii
peak
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/180,399
Inventor
Louis Crocker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to US10/180,399 priority Critical patent/US20020198238A1/en
Publication of US20020198238A1 publication Critical patent/US20020198238A1/en
Priority to US10/342,379 priority patent/US20030144327A1/en
Priority to US10/660,936 priority patent/US6858631B1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Definitions

  • the present invention relates to polymorphic, amorphous and hydrated forms of the title compound which has the chemical structure shown below:
  • the compound is a potent and selective cyclooxygenase-2 (COX-2) inhibitor, useful primarily in the treatment of inflammation, pain and fever as well as other COX-2 mediated diseases, such as described in PCT Publication Nos. WO 96/10012 and WO 96/16934.
  • COX-2 cyclooxygenase-2
  • Compound A is described in U.S. Pat. No. 5,861,419 granted on Jan. 19, 1999 (Example 23) incorporated by reference in its entirety.
  • Bipyridyl compounds generally are highly crystalline, poorly water soluble and hydrophobic, resulting in difficulties in the preparation of pharmaceutical formulations and problems associated with bioavailability. Accordingly, efforts were made to discover other forms of Compound A and to investigate the properties thereof. There were discovered three additional polymorphic forms, an amorphous form and two hydrates.
  • Polymorphic forms of Compound A are identified as Form I (onset of melting, m.p. 134-136° C., peak m.p. 138° C.), Form II (onset of melting, m.p ⁇ 131° C., peak m.p. 133° C.), Form III (onset of melting, m.p. ⁇ 133° C., peak m.p. 135° C.) and Form IV (onset of melting, m.p. ⁇ 134° C., peak m.p. 136° C).
  • Forms I through IV are anhydrous. An amorphous form and two hydrates have also been identified.
  • FIG. 1 is the X-ray powder diffraction (XRPD) pattern of Form I;
  • FIG. 2 is the XRPD pattern of Form II
  • FIG. 3 is the XRPD pattern of Form III
  • FIG. 4 is the XRPD pattern of Form IV
  • FIG. 5 is the XRPD pattern of the hemihydrate
  • FIG. 6 is the XRPD pattern of the sesquihydrate
  • FIG. 7 is a thermogravimetric (TG) scan of the hemihydrate
  • FIG. 8 is a TG scan of the sesquihydrate.
  • Polymorphic forms of Compound A are identified as Form I (onset of melting, m.p. 134-136° C., peak m.p. 138° C.), Form II (onset of melting, m.p ⁇ 131° C., peak m.p. 133° C.), Form III (onset of melting, m.p. ⁇ 133° C., peak m.p. 135° C.) and Form IV (onset of melting, m.p. ⁇ 134° C., peak m.p. 136° C.).
  • Forms I through IV are anhydrous. An amorphous form and two hydrates have also been identified.
  • polymorphs of the present invention are synthesized in accordance with the following examples which are illustrative.
  • the starting material compound A is made in accordance with Example 23 of U.S. Pat. No. 5,861,419 granted on Jan. 19, 1999.
  • Form II is obtained by crystallizing compound A obtained in accordance with Preparative Example 1 from ethyl acetate.
  • Form I was obtained by recrystallizing Form II obtained as described in Example 1 from a solvent mixture of isopropanol/hexane.
  • Form IV is alternatively prepared by contacting Form I as described in Example 2 with an organic solvent, e.g., toluene and heptane, and then recrystallizing at a temperature less than 45° C., such as about 15° C.
  • organic solvent e.g., toluene and heptane
  • Form IV is also alternatively prepared by dissolving Form II in an organic solvent, such as toluene and heptane, and then recrystallizing at a temperature less than 45° C., such as about 15° C.
  • organic solvent such as toluene and heptane
  • Form III was prepared by stirring Form IV from Example 3 in water for 1 day, and then dehydrating at 90° C. in vacuo until Form III is present.
  • the melting temperature onset was ca. 133° C. with an enthalpy of fusion of approximately 24 kJ/mol.
  • the peak melting temperature was 135° C.
  • the hemihydrate form of compound A is produced by stirring Form IV obtained in accordance with Example 3 in water for at least 1 day.
  • XRPD analysis of the solid produced a diffractogram identical to previous hemihydrate samples obtained for Form II.
  • Thermogravimetry confirmed that Form IV had converted to the hemihydrate form, exhibiting a sharp weight loss of 2.45% on heating,which corresponds to a mole ratio of water to drug of 0.50%.
  • the sesquihydrate of compound A is obtained by combining Form I in accordance with Example 2 and water (approximately 1.5 mol/mol compound).
  • the amorphous form of compound A is obtained by heating any polymorph to above its melting temperature (for example to 145° C.) under nitrogen, followed by quench cooling to room temperature under a dry atmosphere.
  • Polymorph I is crystalline by XRPD using a Scintag XDS-2000, Si(Li) Peltier-cooled solid state detector using a Cu K alpha source at 45 kV and 40 mA, and divergent beam (2 mm and 4 mm) and receiving beam slits (0.5 mm and 0.2 mm). Peak positions were calibrated using a standard silicon disk (97.5% pure).
  • Temperature XRPD studies were carried out under nitrogen, using a gold-plated copper stage with a Beryllium window on the cover.
  • a Micristar temperature controller monitored and controlled the temperatures.
  • Table 1 lists the XRPD peak locations for Forms I, II, III and IV. TABLE 1 X-ray Crystalline Reflections in ° 2 theta That Are Characteristic of Polymorphs I, II, III and IV using Cu K alpha Form I Form II Form III Form IV 7.1 5.6 8.7 9.7 9.4 10.5 11.8 10.7 16.1 15.5 17.6 15.2 20.1 17.1 19.5 22.7 22.4 21.7 24.1 23.5 23.6
  • XRPD patterns for Forms I-IV are shown in FIGS. 1 - 4 .
  • XRPD patterns for the two hydrate forms are shown in FIGS. 5 and 6.
  • the extrapolated melting temperature onset of Form I was 134.0 ⁇ 0.6° C. with an enthalpy of fusion of 27.2 ⁇ 0.9 kJ/mol at 10 deg/min under nitrogen in crimped aluminum pans (FIG. 1).
  • the peak melting temperature was 138° C.
  • the melting temperature onset and enthalpy of fusion of Form I were slightly higher than those observed for Form II. These polymorphic forms do not recrystallize upon cooling from the melt nor do they recrystallize on reheating.
  • the glass transition temperature of the amorphous form (mid-point, 10K/min, crimped aluminum pan) is 55° C.
  • Table 2 provides a comparison of the extrapolated melting temperature onset, T 0 , and the enthalpy of fusion, ⁇ H, for Forms I, II, III and IV.
  • Extrapolated melting temperature onset, T o , and Enthalpy of Fusion obtained by DSC at 10K/min in crimped pans under nitrogen Polymorphic form T o (° C.)
  • Enthalpy of fusion kJ/mol Form I 134.0 ⁇ 0.6 27.2 ⁇ 0.9 Form II 131 ⁇ 1 25.8 ⁇ 0.2 Form III 133 22.7 Form IV 134.0 ⁇ 0.1 27.9 ⁇ 0.2
  • the DSC thermogram for Form IV obtained at a scanning rate of 10° C./min under nitrogen in crimped aluminum pans, consisted of a single symmetrical endotherm with a mean onset melting point of 134.0 ⁇ 0.1° C. and a heat of fusion of 27.9 kJ/mol. A scanning rate of 2° C./min confirmed that the observed endotherm was due to a single endothermic transition. The enthalpy of fusion of the different polymorphs are also similar.
  • Forms I and IV have similar solubilities. Form IV is slightly less soluble and slightly more stable at temperatures below 45° C. Forms I and IV are enantiotropic with Form IV converting to Form I at temperatures greater than 45° C. when in contact with organic solvents.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Polymorphic, amorphous and hydrated forms of the title compound having the following structure:
Figure US20020198238A1-20021226-C00001
are disclosed. The compound is a potent and selective cyclooxygenase-2 (COX-2) inhibitor.

Description

    BACKGROUND OF THE INVENTION
  • The present invention relates to polymorphic, amorphous and hydrated forms of the title compound which has the chemical structure shown below: [0001]
    Figure US20020198238A1-20021226-C00002
  • The compound is a potent and selective cyclooxygenase-2 (COX-2) inhibitor, useful primarily in the treatment of inflammation, pain and fever as well as other COX-2 mediated diseases, such as described in PCT Publication Nos. WO 96/10012 and WO 96/16934. Compound A is described in U.S. Pat. No. 5,861,419 granted on Jan. 19, 1999 (Example 23) incorporated by reference in its entirety. [0002]
  • Bipyridyl compounds generally are highly crystalline, poorly water soluble and hydrophobic, resulting in difficulties in the preparation of pharmaceutical formulations and problems associated with bioavailability. Accordingly, efforts were made to discover other forms of Compound A and to investigate the properties thereof. There were discovered three additional polymorphic forms, an amorphous form and two hydrates. [0003]
    • SUMMARY OF THE INVENTION
  • Polymorphic forms of Compound A, for purposes of this invention, are identified as Form I (onset of melting, m.p. 134-136° C., peak m.p. 138° C.), Form II (onset of melting, m.p ˜131° C., peak m.p. 133° C.), Form III (onset of melting, m.p.˜133° C., peak m.p. 135° C.) and Form IV (onset of melting, m.p.˜134° C., peak m.p. 136° C). Forms I through IV are anhydrous. An amorphous form and two hydrates have also been identified.[0004]
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • The invention is described in connection with the appended drawings in which: [0005]
  • FIG. 1 is the X-ray powder diffraction (XRPD) pattern of Form I; [0006]
  • FIG. 2 is the XRPD pattern of Form II; [0007]
  • FIG. 3 is the XRPD pattern of Form III; [0008]
  • FIG. 4 is the XRPD pattern of Form IV; [0009]
  • FIG. 5 is the XRPD pattern of the hemihydrate; [0010]
  • FIG. 6 is the XRPD pattern of the sesquihydrate; [0011]
  • FIG. 7 is a thermogravimetric (TG) scan of the hemihydrate, and [0012]
  • FIG. 8 is a TG scan of the sesquihydrate.[0013]
    • DETAILED DESCRIPTION
  • Polymorphic forms of Compound A, for purposes of this invention, are identified as Form I (onset of melting, m.p. 134-136° C., peak m.p. 138° C.), Form II (onset of melting, m.p ˜131° C., peak m.p. 133° C.), Form III (onset of melting, m.p.˜133° C., peak m.p. 135° C.) and Form IV (onset of melting, m.p.˜134° C., peak m.p. 136° C.). Forms I through IV are anhydrous. An amorphous form and two hydrates have also been identified. [0014]
  • The polymorphs of the present invention are synthesized in accordance with the following examples which are illustrative. [0015]
    • Preparative Example 1
  • The starting material compound A is made in accordance with Example 23 of U.S. Pat. No. 5,861,419 granted on Jan. 19, 1999. [0016]
    • EXAMPLE 1 Form II
  • Form II is obtained by crystallizing compound A obtained in accordance with Preparative Example 1 from ethyl acetate. [0017]
  • Differential Scanning Calorimetry showed an extrapolated onset of melting at 131±1° C., and a peak melting point of 132.5±0.1° C. [0018]
    • EXAMPLE 2 Form I
  • Form I was obtained by recrystallizing Form II obtained as described in Example 1 from a solvent mixture of isopropanol/hexane. [0019]
    • EXAMPLE 3 Form IV
  • Form IV appeared spontaneously in batches of compound A prepared as in Preparative Example 1. [0020]
  • Form IV is alternatively prepared by contacting Form I as described in Example 2 with an organic solvent, e.g., toluene and heptane, and then recrystallizing at a temperature less than 45° C., such as about 15° C. [0021]
  • Form IV is also alternatively prepared by dissolving Form II in an organic solvent, such as toluene and heptane, and then recrystallizing at a temperature less than 45° C., such as about 15° C. [0022]
    • EXAMPLE 4 Form III
  • Form III was prepared by stirring Form IV from Example 3 in water for 1 day, and then dehydrating at 90° C. in vacuo until Form III is present. The melting temperature onset was ca. 133° C. with an enthalpy of fusion of approximately 24 kJ/mol. The peak melting temperature was 135° C. [0023]
  • Alternatively, using the hemihydrate of Example 5, conducting a temperature XRPD of the hemihydrate at 130° C. resulted in the production of Form III. [0024]
    • EXAMPLE 5 Hemihydrate
  • The hemihydrate form of compound A is produced by stirring Form IV obtained in accordance with Example 3 in water for at least 1 day. XRPD analysis of the solid produced a diffractogram identical to previous hemihydrate samples obtained for Form II. Thermogravimetry confirmed that Form IV had converted to the hemihydrate form, exhibiting a sharp weight loss of 2.45% on heating,which corresponds to a mole ratio of water to drug of 0.50%. [0025]
    • EXAMPLE 6 Sesquihydrate
  • The sesquihydrate of compound A is obtained by combining Form I in accordance with Example 2 and water (approximately 1.5 mol/mol compound). [0026]
    • EXAMPLE 7 Amorphous
  • The amorphous form of compound A is obtained by heating any polymorph to above its melting temperature (for example to 145° C.) under nitrogen, followed by quench cooling to room temperature under a dry atmosphere. [0027]
    • Characterization of Polymorphs
  • The polymorphic forms of compound A are characterized using the following procedures. [0028]
  • X-Ray Powder Diffraction Pattern Analysis [0029]
  • Polymorph I is crystalline by XRPD using a Scintag XDS-2000, Si(Li) Peltier-cooled solid state detector using a Cu K alpha source at 45 kV and 40 mA, and divergent beam (2 mm and 4 mm) and receiving beam slits (0.5 mm and 0.2 mm). Peak positions were calibrated using a standard silicon disk (97.5% pure). [0030]
  • Temperature XRPD studies were carried out under nitrogen, using a gold-plated copper stage with a Beryllium window on the cover. A Micristar temperature controller monitored and controlled the temperatures. [0031]
  • Temperature XRPD studies demonstrated that the compound did not undergo any transitions prior to melting, which was complete at 140° C., and that there was no conversion to a different polymorphic form. Similar results were obtained for Form II. The material remained amorphous and did not recrystallize. [0032]
  • Table 1 below lists the XRPD peak locations for Forms I, II, III and IV. [0033]
    TABLE 1
    X-ray Crystalline Reflections in ° 2 theta That Are Characteristic of
    Polymorphs I, II, III and IV using Cu K alpha
    Form I Form II Form III Form IV
    7.1 5.6 8.7
    9.7 9.4 10.5
    11.8 10.7 16.1
    15.5 17.6 15.2
    20.1 17.1
    19.5
    22.7 22.4 21.7
    24.1 23.5
    23.6
  • XRPD patterns for Forms I-IV are shown in FIGS. [0034] 1-4. XRPD patterns for the two hydrate forms are shown in FIGS. 5 and 6.
  • Differential Scanning Calorimetry (DSC) [0035]
  • The extrapolated melting temperature onset of Form I was 134.0±0.6° C. with an enthalpy of fusion of 27.2±0.9 kJ/mol at 10 deg/min under nitrogen in crimped aluminum pans (FIG. 1). The peak melting temperature was 138° C. [0036]
  • When measured using a TA Instruments DSC2910 instrument, at 10° C./min under a nitrogen atmosphere in an open aluminum pan, the onset of melting was 136° C. and the peak melting temperature was as described above. There were no significant changes with DSC scanning rate other than the expected shift in peak temperature. DSC thermal behaviour of Form I in crimped sample pans under nitrogen (60 mL/min) was measured using a Seiko robotic DSC (RDC-220) at 2, 10 and 20 deg/min. The DSC was calibrated for temperature and heat flow with gallium, indium and tin. [0037]
  • The melting temperature onset and enthalpy of fusion of Form I were slightly higher than those observed for Form II. These polymorphic forms do not recrystallize upon cooling from the melt nor do they recrystallize on reheating. The glass transition temperature of the amorphous form (mid-point, 10K/min, crimped aluminum pan) is 55° C. [0038]
  • Table 2 provides a comparison of the extrapolated melting temperature onset, T[0039] 0, and the enthalpy of fusion, ΔH, for Forms I, II, III and IV.
    TABLE 2
    Extrapolated melting temperature onset, To, and Enthalpy of Fusion
    obtained by DSC at 10K/min in crimped pans under nitrogen
    Polymorphic form To (° C.) Enthalpy of fusion, kJ/mol
    Form I 134.0 ± 0.6 27.2 ± 0.9
    Form II 131 ± 1 25.8 ± 0.2
    Form III 133 22.7
    Form IV 134.0 ± 0.1 27.9 ± 0.2
  • The DSC thermogram for Form IV, obtained at a scanning rate of 10° C./min under nitrogen in crimped aluminum pans, consisted of a single symmetrical endotherm with a mean onset melting point of 134.0±0.1° C. and a heat of fusion of 27.9 kJ/mol. A scanning rate of 2° C./min confirmed that the observed endotherm was due to a single endothermic transition. The enthalpy of fusion of the different polymorphs are also similar. [0040]
  • Forms I and IV have similar solubilities. Form IV is slightly less soluble and slightly more stable at temperatures below 45° C. Forms I and IV are enantiotropic with Form IV converting to Form I at temperatures greater than 45° C. when in contact with organic solvents. [0041]

Claims (9)

What is claimed is:
1. A polymorph of Compound A of structural formula:
Figure US20020198238A1-20021226-C00003
selected from Forms II, III and IV having the physical characteristics described in the following Table:
Form II III IV DSC 134-136° C. 133° C. 134° C. extrapolated melting temperature onset XRPD (peak 5.6 10.5 8.7 positions, Cu K 9.4 16.1 15.2 alpha) 10.7 22.4 17.1 17.6 19.5 21.7 23.5 23.6
2. A polymorph in accordance with claim 1 which is Form IV.
3. A sesquihydrate of Form I having a DSC of about 134-136° C., peak m.p. 138° C., an XRPD pattern of 7.1, 9.7, 11.8, 15.5, 20.1, 22.7 and 24.1, and further containing approximately 1.5 mol water per mol of compound A.
4. A polymorph in accordance with claim 1 which is Form IV.
5. A hemihydrate of Form IV in accordance with claim 4 containing 0.5 mol water per mol of compound A.
6. A polymorph in accordance with claim 1 which is Form III.
7. An amorphous form of Compound A in accordance with claim 1 obtained by cooling a molten sample of a crystalline form of Compound A.
8. A pharmaceutical composition comprised of a polymorph II, III or IV in accordance with claim 1 in combination with a pharmaceutically acceptable carrier.
9. A Form II polymorph of Compound A of structural formula:
Figure US20020198238A1-20021226-C00004
having a DSC extrapolated melting temperature onset of ˜131° C., and XRPD peak positions, Cu K alpha of 5.6, 9.4, 10.7 and 17.6.
US10/180,399 1999-11-29 2002-06-26 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl Abandoned US20020198238A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/180,399 US20020198238A1 (en) 1999-11-29 2002-06-26 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
US10/342,379 US20030144327A1 (en) 1999-11-29 2003-01-14 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
US10/660,936 US6858631B1 (en) 1999-11-29 2003-09-12 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16792299P 1999-11-29 1999-11-29
US09/724,522 US6441002B1 (en) 1999-11-29 2000-11-28 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonyphenyl)-6'- methyl-[2,3']bipyridinyl
US10/180,399 US20020198238A1 (en) 1999-11-29 2002-06-26 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/724,522 Division US6441002B1 (en) 1999-11-29 2000-11-28 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonyphenyl)-6'- methyl-[2,3']bipyridinyl

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/342,379 Continuation US20030144327A1 (en) 1999-11-29 2003-01-14 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Publications (1)

Publication Number Publication Date
US20020198238A1 true US20020198238A1 (en) 2002-12-26

Family

ID=22609368

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/724,522 Expired - Lifetime US6441002B1 (en) 1999-11-29 2000-11-28 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonyphenyl)-6'- methyl-[2,3']bipyridinyl
US10/180,399 Abandoned US20020198238A1 (en) 1999-11-29 2002-06-26 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
US10/342,379 Abandoned US20030144327A1 (en) 1999-11-29 2003-01-14 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/724,522 Expired - Lifetime US6441002B1 (en) 1999-11-29 2000-11-28 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonyphenyl)-6'- methyl-[2,3']bipyridinyl

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/342,379 Abandoned US20030144327A1 (en) 1999-11-29 2003-01-14 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Country Status (11)

Country Link
US (3) US6441002B1 (en)
EP (1) EP1248618B1 (en)
JP (1) JP4425514B2 (en)
AT (1) ATE320809T1 (en)
AU (1) AU776544B2 (en)
CA (1) CA2391650C (en)
DE (1) DE60026877T2 (en)
DK (1) DK1248618T3 (en)
ES (1) ES2259295T3 (en)
PT (1) PT1248618E (en)
WO (1) WO2001037833A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) * 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
EP2479166B1 (en) 2009-02-27 2014-08-20 Cadila Healthcare Limited A process for the preparation of etoricoxib
SI2714676T1 (en) 2011-05-27 2019-06-28 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
EP2773618A1 (en) 2011-11-03 2014-09-10 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
WO2013144977A2 (en) * 2012-03-30 2013-10-03 Mylan Laboratories Ltd. An improved process for the preparation of etoricoxib
EP2888231B1 (en) 2012-08-27 2019-01-09 Glenmark Pharmaceuticals Limited Process for preparation of crystalline etoricoxib
CN104418799A (en) * 2013-09-03 2015-03-18 天津药物研究院 Etoricoxib crystal as well as preparation method and application thereof
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN107056691B (en) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 Method for preparing etoricoxib crystal form V
WO2019130049A1 (en) 2017-12-29 2019-07-04 Grünenthal GmbH Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain
CN111410629A (en) * 2020-03-31 2020-07-14 天津大学 Etoricoxib solvate and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321033A (en) 1991-11-15 1994-06-14 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds useful for treating inflammatory diseases
HU227732B1 (en) 1996-07-18 2012-01-30 Merck Frosst Canada Ltd Substituted pyridine derivatives as selective cyclooxigenase-2 inhibitors and use thereof
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
AU759469B2 (en) 1998-04-24 2003-04-17 Merck Sharp & Dohme Corp. Process for synthesizing cox-2 inhibitors
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis

Also Published As

Publication number Publication date
EP1248618A4 (en) 2003-05-14
AU776544B2 (en) 2004-09-16
EP1248618A1 (en) 2002-10-16
CA2391650C (en) 2011-01-25
DE60026877D1 (en) 2006-05-11
ES2259295T3 (en) 2006-10-01
JP4425514B2 (en) 2010-03-03
DK1248618T3 (en) 2006-07-10
EP1248618B1 (en) 2006-03-22
WO2001037833A1 (en) 2001-05-31
DE60026877T2 (en) 2006-11-23
US20030144327A1 (en) 2003-07-31
JP2003514859A (en) 2003-04-22
ATE320809T1 (en) 2006-04-15
CA2391650A1 (en) 2001-05-31
AU1803101A (en) 2001-06-04
PT1248618E (en) 2006-07-31
US6441002B1 (en) 2002-08-27

Similar Documents

Publication Publication Date Title
US6441002B1 (en) Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonyphenyl)-6'- methyl-[2,3']bipyridinyl
JP5411734B2 (en) Polymorphic form of 1-4- (5-cyanoindol-3-yl) butyl-4- (2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
KR102142797B1 (en) Crystalline forms of mesylate salts of pyridinylaminopyrimidine derivatives, methods for their preparation, and uses thereof
KR102081920B1 (en) Novel crystalline form of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine salt
WO2001092230A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
EP2350009B1 (en) Sulfonate salts of flupirtine
US6858631B1 (en) Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
US6521642B2 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
AU2001292907A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
KR20040104677A (en) Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
US8552193B2 (en) Alternative forms of the phosphodiesterase-4 inhibitor N-cyclopropyl-1-{3-[(1-oxidopryidin-3-yl)ethynyl]phenyl}-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxyamide
US6800647B2 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
KR102496869B1 (en) NOVEL SALT OF IMIDAZO[1,2-a]PYRIDINE COMPOUND, CRYSTALLINES THEREOF AND PREPARATION METHODS
JP6985137B2 (en) Crystal form of sulfonamide compound
WO2021259316A1 (en) Crystalline form of compound
WO2010097583A1 (en) Esomeprazole potassium polymorph and its preparation
KR20230165774A (en) Solid form of CYP11A1 inhibitor with 4H-pyran-4-one structure
KR20070030962A (en) Processes for preparing novel crystal forms of ondansetron

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION